{"date":"2026-07-06","count":24,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4116-2026-07-06-2052-gybssj","company_id":"4116","company":"明基醫","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"20:52:34","subject":"（補充115/06/30公告）代子公司明基健康生活公告董事會決議出售所持合躍生活廣場事業普通股。","clause":"第20款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：明基醫（4116），2026-07-06 20:52，「（補充115/06/30公告）代子公司明基健康生活公告董事會決議出售所持合躍生活廣場事業普通股。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-07-06-2002-1evbso3","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-07-06","time":"20:02:24","subject":"代重要子公司Belite Bio, Inc公告受邀參加Piper Sandler線上眼科投資人論壇(Piper Sandler Virtual OphthalmologyInvestor Symposium)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-07-06 20:02，「代重要子公司Belite Bio, Inc公告受邀參加Piper Sandler線上眼科投資人論壇(Piper Sand」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6472-2026-07-06-1931-wii5x","company_id":"6472","company":"保瑞","market":"上市","industry":"生技醫療","date":"2026-07-06","time":"19:31:47","subject":"公告本公司決議現金股利配息基準日（更正及補充說明公告12.至16.）","clause":"第14款","fact_date":"2026-07-03","cite_as":"公開資訊觀測站重大訊息：保瑞（6472），2026-07-06 19:31，「公告本公司決議現金股利配息基準日（更正及補充說明公告12.至16.）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-07-06-1919-1yo817c","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-07-06","time":"19:19:09","subject":"代重要子公司Belite Bio, Inc公告受邀參加美國視網膜專家學會2026年會（ASRS 2026）","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-07-06 19:19，「代重要子公司Belite Bio, Inc公告受邀參加美國視網膜專家學會2026年會（ASRS 2026）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-07-06-1918-nn5cyz","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-07-06","time":"19:18:41","subject":"代重要子公司Belite Bio, Inc公告受邀參加第63屆國際臨床視覺電生理學會年會（ISCEV 2026）","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-07-06 19:18，「代重要子公司Belite Bio, Inc公告受邀參加第63屆國際臨床視覺電生理學會年會（ISCEV 2026）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6659-2026-07-06-1819-vkfgz5","company_id":"6659","company":"天明製藥","market":"興櫃","industry":"生技醫療","date":"2026-07-06","time":"18:19:17","subject":"公告本公司薪資報酬委員會委員名單。","clause":"第6款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：天明製藥（6659），2026-07-06 18:19，「公告本公司薪資報酬委員會委員名單。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6659-2026-07-06-1818-npkafu","company_id":"6659","company":"天明製藥","market":"興櫃","industry":"生技醫療","date":"2026-07-06","time":"18:18:40","subject":"公告本公司董事會通過選任董事長。","clause":"第6款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：天明製藥（6659），2026-07-06 18:18，「公告本公司董事會通過選任董事長。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3716-2026-07-06-1742-1xlrqql","company_id":"3716","company":"中化控股","market":"上市","industry":"生技醫療","date":"2026-07-06","time":"17:42:30","subject":"公告本公司董事長訂定配息基準日及調整配息率","clause":"第14款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：中化控股（3716），2026-07-06 17:42，「公告本公司董事長訂定配息基準日及調整配息率」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4744-2026-07-06-1738-11mi7kj","company_id":"4744","company":"皇將","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"17:38:01","subject":"更正115年股東會議事錄部份資訊","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：皇將（4744），2026-07-06 17:38，「更正115年股東會議事錄部份資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6574-2026-07-06-1722-1lvzn4z","company_id":"6574","company":"霈方","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"17:22:56","subject":"公告本公司董事會決議修訂「115年度員工認股權憑證發行及認股辦法」","clause":"第11款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：霈方（6574），2026-07-06 17:22，「公告本公司董事會決議修訂「115年度員工認股權憑證發行及認股辦法」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6574-2026-07-06-1721-1egfkms","company_id":"6574","company":"霈方","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"17:21:44","subject":"公告本公司董事會通過重要決議","clause":"第53款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：霈方（6574），2026-07-06 17:21，「公告本公司董事會通過重要決議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3164-2026-07-06-1700-ac89kl","company_id":"3164","company":"景岳","market":"上市","industry":"生技醫療","date":"2026-07-06","time":"17:00:00","subject":"公告本公司申請股票上櫃轉上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：景岳（3164），2026-07-06 17:00，「公告本公司申請股票上櫃轉上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4127-2026-07-06-1629-xi10em","company_id":"4127","company":"天良","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"16:29:13","subject":"公告本公司董事會決議召開115年第一次股東臨時會日期及相關事宜(因應電子投票自動轉入格式規定，特此更正。)","clause":"第17款","fact_date":"2026-06-12","cite_as":"公開資訊觀測站重大訊息：天良（4127），2026-07-06 16:29，「公告本公司董事會決議召開115年第一次股東臨時會日期及相關事宜(因應電子投票自動轉入格式規定，特此更正。)」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4147-2026-07-06-1614-syvimc","company_id":"4147","company":"中裕","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"16:14:07","subject":"公告本公司愛滋病新藥Trogarzo生物製劑獲得台灣衛生福利部食品藥物管理署（TFDA）領證通知","clause":"第10款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：中裕（4147），2026-07-06 16:14，「公告本公司愛滋病新藥Trogarzo生物製劑獲得台灣衛生福利部食品藥物管理署（TFDA）領證通知」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6986-2026-07-06-1550-18bhctm","company_id":"6986","company":"和迅","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"15:50:30","subject":"公告本公司初次上櫃掛牌首五個營業日穩定價格操作結果","clause":"第53款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：和迅（6986），2026-07-06 15:50，「公告本公司初次上櫃掛牌首五個營業日穩定價格操作結果」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6785-2026-07-06-1531-182uyqk","company_id":"6785","company":"昱展新藥","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"15:31:39","subject":"公告本公司收到「LONG-ACTING INJECTABLE FORMULATIONSOF KETAMINE PAMOATE SALTS」印度專利核准通知書及證書。","clause":"第53款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：昱展新藥（6785），2026-07-06 15:31，「公告本公司收到「LONG-ACTING INJECTABLE FORMULATIONSOF KETAMINE PAMOA」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4127-2026-07-06-1530-omddu7","company_id":"4127","company":"天良","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"15:30:57","subject":"公告本公司董事轉讓持股超過選任時持股之二分之一，依法其董事職務當然解任","clause":"第6款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：天良（4127），2026-07-06 15:30，「公告本公司董事轉讓持股超過選任時持股之二分之一，依法其董事職務當然解任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6794-2026-07-06-1526-1yawxnn","company_id":"6794","company":"向榮生技","market":"上市","industry":"生技醫療","date":"2026-07-06","time":"15:26:41","subject":"本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎(Knee Osteoarthritis)之人體臨床試驗設計增加期中分析提早取得關鍵療效數據獲衛生福利部核准變更","clause":"第10款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：向榮生技（6794），2026-07-06 15:26，「本公司脂肪幹細胞新藥ELIXCYTE治療膝骨關節炎(Knee Osteoarthritis)之人體臨床試驗設計增加期中分」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7814-2026-07-06-1510-z6rxem","company_id":"7814","company":"海昌生技","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"15:10:11","subject":"公告本公司股票初次上櫃前現金增資發行新股承銷價格","clause":"第44款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：海昌生技（7814），2026-07-06 15:10，「公告本公司股票初次上櫃前現金增資發行新股承銷價格」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-3176-2026-07-06-1452-n3osjp","company_id":"3176","company":"基亞","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"14:52:01","subject":"代重要子公司MVA公告全體董事簽署重要決議","clause":"第10款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：基亞（3176），2026-07-06 14:52，「代重要子公司MVA公告全體董事簽署重要決議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6461-2026-07-06-1356-1aq7iqo","company_id":"6461","company":"益得","market":"上櫃","industry":"生技醫療","date":"2026-07-06","time":"13:56:23","subject":"本公司受邀參加元大證券舉辦之法人說明會","clause":"第12款","fact_date":"2026-07-23","cite_as":"公開資訊觀測站重大訊息：益得（6461），2026-07-06 13:56，「本公司受邀參加元大證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-1795-2026-07-06-1134-1fqkmsr","company_id":"1795","company":"美時","market":"上市","industry":"生技醫療","date":"2026-07-06","time":"11:34:30","subject":"澄清媒體報導","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：美時（1795），2026-07-06 11:34，「澄清媒體報導」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7729-2026-07-06-0631-198ctbw","company_id":"7729","company":"仲恩生醫","market":"興櫃","industry":"生技醫療","date":"2026-07-06","time":"06:31:39","subject":"衛生福利部核准本公司之新藥產品Stemchymal核定列入「臺灣再生醫療製劑輔導專案(T-RMAT)」","clause":"第44款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：仲恩生醫（7729），2026-07-06 06:31，「衛生福利部核准本公司之新藥產品Stemchymal核定列入「臺灣再生醫療製劑輔導專案(T-RMAT)」」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7878-2026-07-06-0611-5u8ocv","company_id":"7878","company":"藥祇","market":"興櫃","industry":"生技醫療","date":"2026-07-06","time":"06:11:00","subject":"公告本公司糖尿病小分子新藥(PS1)之第一期臨床試驗初步結果（Topline Results）","clause":"第8款","fact_date":"2026-07-06","cite_as":"公開資訊觀測站重大訊息：藥祇（7878），2026-07-06 06:11，「公告本公司糖尿病小分子新藥(PS1)之第一期臨床試驗初步結果（Topline Results）」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}